NACDS is lauding legislation introduced by U.S. Senators Peter Welch (D-VT) and Roger Marshall (R-KS) to crack down on tactics by which “pharmaceutical benefit manipulator” middlemen maximize profits at the expense of patients, pharmacies, and others.
NYRx puts patients over PBMs in the state’s Medicaid pharmacy benefit.
On March 26, a study conducted by the University of Pittsburgh School of Pharmacy Program Evaluation and Research Unit (PERU) and funded by the National Association of Chain Drug Stores (NACDS) Foundation was published in the American Journal of Drug and Alcohol Abuse (AJDAA).
Statement defines specific solutions for patient-manipulation by “PBMs” and urges continued bipartisan work on this critical issue.
Traupe brings 30 years of combined experience in CIA and U.S. Marine Corps; will explore current global threats.
96 percent of those 65 and older say it is “very easy” or “somewhat easy” to access pharmacies – making them the most accessible healthcare destination tested in a national poll.
As part of the study, community-based pharmacists and pharmacy teams worked collaboratively to proactively identify and initiate statin therapy for individuals with Type 2 diabetes.
NACDS President and Chief Executive Officer Steven C. Anderson issued the following statement today upon passage of the Pharmacy Benefit Manager Transparency Act (S. 127) by the U.S. Senate Commerce, Science, and Transportation Committee:
Announces updated national, state, and Congressional District polling relevant to priority issues.
The Drug Price Transparency in Medicaid Act will protect patients, pharmacies, and others from middlemen tactics that drive up prescription drug prices.
